Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AKTX - Akari Therapeutics Plc

Previous close
1.005
0   0%

Share volume: 600
Last Updated: Fri 27 Dec 2024 06:42:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$1.00
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 22%
Liquidity 28%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.16%
1 Month
-12.50%
3 Months
-66.67%
6 Months
-62.74%
1 Year
-68.79%
2 Year
-88.86%
Key data
Stock price
$1.00
P/E Ratio 
0.00
DAY RANGE
$0.98 - $1.00
EPS 
$0.00
52 WEEK RANGE
$1.01 - $4.40
52 WEEK CHANGE
-$68.59
MARKET CAP 
46.514 M
YIELD 
N/A
SHARES OUTSTANDING 
12.145 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$53,224
AVERAGE 30 VOLUME 
$55,090
Company detail
CEO: Rachelle Jacques
Region: US
Website: akaritx.com
Employees: 9
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Akari Therapeutics, Plc focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.

Recent news